1046. Week 48 Outcomes from the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults with HIV

Debbie Hagins,Princy Kumar,Michael S. Saag,Anson K. Wurapa,Indira Brar,Daniel S. Berger,Olayemi Osiyemi,Corrilynn O. Hileman,Moti Ramgopal,Cheryl McDonald,Christiana Blair,Kristen Andreatta,Sean E. Collins,Diana M. Brainard,Hal Martin

1046. Week 48 Outcomes from the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults with HIV

2020

Debbie Hagins
Princy Kumar
Michael S. Saag
Anson K. Wurapa
Indira Brar
Daniel S. Berger
Olayemi Osiyemi
Corrilynn O. Hileman
Moti Ramgopal
Cheryl McDonald
Christiana Blair
Kristen Andreatta
Sean E. Collins
Diana M. Brainard
Hal Martin

Background Black Americans are disproportionately impacted by HIV. The BRAAVE 2020 study, evaluated the safety and efficacy of switching to the guidelines-recommended single-tablet regimen bictegravir, emtricitabine, tenofovir alafenamide (B/F/TAF) in Black adults through week (W) 48.

Keywords:

human immunodeficiency virus
Internal medicine
Medicine
african american

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations